Clinical Trial Update: Safety of and Immune Response to an HIV-1 Subtype C Vaccine (AVX101) in HIV Uninfected Adults [Phase 1]

View source ↗

Summary

Phase 1 study update evaluating the safety and immune response of AVX101, an HIV-1 subtype C vaccine, in HIV-uninfected adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• AVX101

Snippet

Sponsor: AlphaVax, Inc. | Conditions: HIV Infections | Phase 1 | Status: COMPLETED